Digestive Disease & Surgery Institute Outcomes
Breast Disease
Breast Disease
Cleveland Clinic’s Comprehensive Breast Cancer Program is one of only 41 comprehensive cancer centers in the nation designated by the National Cancer Institute. Cleveland Clinic’s 5 multidisciplinary comprehensive breast center locations (Fairview Hospital, Hillcrest Hospital, Beachwood Family Health Center, Strongsville Family Health Center, and Cleveland Clinic main campus) have achieved full accreditation from the American College of Surgeons' National Accreditation Program for Breast Centers (NAPBC).
The multidisciplinary physician team of highly skilled specialists provides comprehensive care to patients with breast cancer. A full array of services ranges from initial screening and diagnosis to high-risk genetic counseling to innovative breast cancer treatment and supportive therapies including counseling services and support groups. The Breast Program specializes in intraoperative radiation therapy, novel targeted therapies and adjuvant therapies for breast cancer, and also in fertility preservation for cancer patients. Our specialists also offer unique specialty clinics for young women with breast cancer, women with high-risk, hereditary breast cancers, women with triple-negative breast cancer and women with central nervous system metastases.
Breast Disease - Percentage of Screening Mammograms Resulting in Callback
2017 - 2022
Cleveland Clinic offers a diagnostic callback program for patients with abnormal screening mammograms.
Data includes Main Campus and Family Health Center locations.
Needle Core or Fine Needle Aspirate Biopsy Prior to Surgical Treatment of Breast Cancerᵃ (N = 2258)
2020-2021
ᵃData from Cleveland Clinic tumor registry for main campus and family health center locations.
Cleveland Clinic's performance was 96%% (1018 of 1065) in 2020 and 95% (1132 of 1193) for this Commission on Cancer standard of care quality measure (95% confidence interval [CI], 97.6-99.7). Cleveland Clinic performs within the acceptable range for biopsy to surgical treatment of breast cancer.
Breast Conservation Surgery for Breast Cancer - Lumpectomy
2017 - 2022
Data are from Digestive Disease Institute only.
Breast Surgery for Breast Cancer - Mastectomy
2017 - 2022
All patients undergoing mastectomy are offered preoperative referral to plastic surgery.
Data includes all breast cancers plus prophylactic mastectomy with breast reconstruction.
Data are from Digestive Disease Institute only.
Immediate Breast Reconstruction
2017 - 2022
Data are from Digestive Disease Institute only.
Fluctuations in 2020 volumes are a result of significant changes to the number of patients treated, which can be directly attributed to the COVID-19 pandemic.
Five-Year Overall Survival of Female Patients With Stages I-III Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N = 9454)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| ER/PR Positive (N = 6995) | 5824 | 5143 | 4327 | 3440 | 2542 |
| HER2 Positive (N = 1336) | 1177 | 1043 | 890 | 727 | 548 |
| Triple-Negative (N = 1123) | 944 | 781 | 635 | 491 | 362 |
ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor
Five-Year Overall Survival of Female Patients With Stageᵃ 0 and I Breast Cancer (N = 7942)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage 0 CC (N = 1965) | 1681 | 1497 | 1240 | 1000 | 751 |
| Stage I CC (N = 5977) | 4821 | 4113 | 3214 | 2462 | 1823 |
CC= Cleveland Clinic, NCDB= National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.
Five-Year Overall Survival of Female Patients With Stageᵃ IIA and IIB Breast Cancer (N = 3608)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage IIA (N = 2455) | 2186 | 1963 | 1696 | 1377 | 974 |
| Stage IIB (N = 1153) | 1007 | 868 | 728 | 574 | 411 |
CC= Cleveland Clinic, NCDB= National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.
Five-Year Overall Survival of Female Patients With Stageᵃ IIIA and IIIB Breast Cancer (N = 937)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage IIIA (N = 602) | 532 | 462 | 386 | 299 | 203 |
| Stage IIIB (N = 335) | 254 | 191 | 125 | 79 | 58 |
CC= Cleveland Clinic, NCDB= National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.
